Key facts, as of
As of November 3, 2026, IDEXX Laboratories (IDXX) trades at $664.23, down 8.1% over the past year. Its 52-week range runs from $500.61 to $769.98; the price is 13.7% below that high. It is 13.7% below its all-time high of $769.98, reached in November 2025. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +414.5%, against +316.3% for the S&P 500 (SPY). It sits 16.1% above its 200-day average of $572.16. Its 30-day volatility is 78.8% annualized, which we rate very high risk. It has a trailing P/E of 44.8.
Cite: Portfolio Terminal, "IDEXX Laboratories (IDXX) stock analysis", 2026-11-03. https://portfolio-terminal.com/analyse/idxx
Where it trades today
trading 61% of the way up its 52-week range
How the price has moved
How far it is from its record
IDEXX Laboratories (IDXX) is 13.7% below its all-time high of $769.98, reached in November 2025. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +414.5%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- IDXX closes above its 50-day average ($538.66) while the 50-day is still under the 200-day ($572.16): a rebound inside a longer decline, not yet an uptrend.
- At $664.23, IDXX is 13.7% below its 1-year high of $769.98, set on November 26, 2025, and 32.7% above its 1-year low of $500.61 (September 11, 2026).
- Over the past month IDXX rose 26.0%, from $527.07 to $664.23.
- IDXX trades at 44.8x its last twelve months of earnings and 39.5x the next twelve months' estimate, so analysts expect earnings 13.3% higher.
- Its P/E is 24.2% above the 36.0x median of the 3 other diagnostics & research companies we track (TMO, DHR, A).
- IDXX's 30-day volatility, 78.8% a year, works out to a typical daily move of about 5.0%.
- Yahoo Finance puts its beta at 1.54: over five years of monthly returns, IDXX moved about 1.54% for each 1% move of the S&P 500.
- The last session traded 0.1x IDXX's average daily volume of the 30 sessions before it.
What would change the read
- The rebound holds while it closes above the 50-day average, $538.66 (−18.9%); it becomes an uptrend when the 50-day climbs 6.2% to cross the 200-day at $572.16.
- A close above $769.98 (+15.9%) would be a new 1-year high; below $500.61 (−24.6%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for IDXX, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under diagnostics & research among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for IDXX by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for IDXX. Last refresh: Nov 3, 2026, 2:31 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Diagnostics & Research.
What IDEXX Laboratories does
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services,…
What analysts expect
IDXX carries a buy consensus from 12 analysts, with an average price target of $694.83 versus $664.23 today (+4.6%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
IDXX generated $4.66B in trailing revenue (9.9% year over year), with a 25.4% net margin, and $1.06B of free cash flow, against $651.34M of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $4.30B | $2.66B | $1.36B | $1.06B | $13.17 | $1.04B |
| 2024 | $3.90B | $2.38B | $1.13B | $887.87M | $10.77 | $798.08M |
| 2023 | $3.66B | $2.19B | $1.10B | $845.04M | $10.17 | $772.88M |
| 2022 | $3.37B | $2.00B | $898.76M | $679.09M | $8.12 | $384.15M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
IDXX is in 21 of the 54 ETFs we track. It weighs most in XLV: 0.69% of the fund, holding #32 of 62.
Famous investors who hold it
IDXX is in the latest 13F of 1 of the 15 famous investors we follow. Terry Smith (Fundsmith) holds the most of it: 3.93% of the portfolio, position #15 of 41, as of Q2 2026.
How its figures compare with those peers
Companies in the same industry
IDXX beside the other companies Yahoo Finance files under diagnostics & research among the assets we track (TMO, DHR, A, largest first).
IDXXyou are here$664.23$52.33B
TMOThermo Fisher Scientific$683.07$253.09BDHDHRDanaher Corporation$228.17$160.40B
AAgilent Technologies$172.78$48.72BWhat the chart is saying
Back above its 50-day average, still under the long-term trend.
recovering- Price is 23.3% above its 50-day average and 16.1% above its 200-day.
- RSI at 74 is overbought: strong momentum, and stretched.
- Nothing above has stopped it this year; the nearest floor is $615.08 (-7.4%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is IDXX valued right now?
IDEXX Laboratories trades at 44.8 times its last twelve months of earnings and 39.5 times the next twelve months' estimate (Yahoo Finance, November 3, 2026). On the chart: back above its 50-day average, still under the long-term trend. Price is 23.3% above its 50-day average and 16.1% above its 200-day.
What is the risk level of IDXX?
Based on 30-day volatility of 78.8%, IDXX has VERY HIGH risk. Its beta of 1.54 means it has swung more than the S&P 500 over the last five years.
Does IDXX pay dividends?
Yahoo Finance shows no dividend yield for IDEXX Laboratories (November 3, 2026).
How far is IDXX from its all-time high?
IDEXX Laboratories is 13.7% below its all-time high of $769.98, reached in November 2025. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +414.5%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold IDXX?
21 of the 54 popular ETFs we track hold IDEXX Laboratories. The largest weights: XLV (0.69%), VO (0.41%), RSP (0.22%), QQQ (0.19%) and QQQM (0.19%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is IDXX?
0.06%, as of September 30, 2026: IDXX is holding #256 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.62 in IDEXX Laboratories.
Which famous investors own IDXX?
Terry Smith (3.93% of Fundsmith's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for IDXX?
The average analyst price target for IDEXX Laboratories (IDXX) is $694.83 based on 12 analyst estimates, about 4.6% above the current price of $664.23. The published range runs from $470.00 to $810.00.
How much revenue does IDXX generate?
IDEXX Laboratories reported $4.66B in trailing twelve-month revenue. Revenue growth is running at 9.9% year over year. Net margin sits at 25.4%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare IDXX with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.